Prostate cancer incidence in Australia correlates inversely with solar radiation

BJU International

Volumn 108, Issue SUPPL.2, 2011, Pages 66-70

  Loke, Tim W ^a   Sevfi, Doruk ^b   Khadra, Mohamed ^b  

^a NEPEAN HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

prostate cancer; solar radiation; sunlight; vitamin D

Indexed keywords

VITAMIN D;

ARTICLE; AUSTRALIA; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; HUMAN; LONG TERM EXPOSURE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; RURAL POPULATION; SOLAR RADIATION; SUN EXPOSURE;

AUSTRALIA; ENVIRONMENTAL EXPOSURE; HUMANS; INCIDENCE; MALE; PROSTATIC NEOPLASMS; RURAL HEALTH; SUNLIGHT; VITAMIN D;

EID: 81455135612     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10736.x     Document Type: Article

References (43)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 (Internet). Lyon, France: International Agency for Research on Cancer, 2010. Available from
2. Schwartz GG, Hulka BS,. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 1990; 10: 1307-11
3. Hanchette CL, Schwartz GG,. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992; 70: 2861-9
4. Australian Bureau of Statistics. ASGC Remoteness Classification: Purpose and Use. Census Paper 03/01, 2003
5. Haddad JG Jr, Hahn TJ,. Natural and synthetic sources of circulating 25-hydroxyvitamin D in man. Nature 1973; 244: 515-7
6. Skowronski RJ, Peehl DM, Feldman D,. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952-60 (Pubitemid 23133240)
7. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D,. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994; 54: 805-10 (Pubitemid 24068341)
8. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP,. 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 1997; 6: 727-32 (Pubitemid 27427629)
9. Zhao XY, Peehl DM, Navone NM, Feldman D,. 1 alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 2000; 141: 2548-56 (Pubitemid 32269075)
10. Gross C, Stamey T, Hancock S, Feldman D,. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998; 159: 2035-9
11. Lokeshwar BL, Schwartz GG, Selzer MG, et al,. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 1999; 8: 241-8 (Pubitemid 29114202)
12. Liu G, Wilding G, Staab MJ, et al,. Phase II study of 1,alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clin Cancer Res 2003; 9: 4077-83 (Pubitemid 37204023)
13. Corder EH, Guess HA, Hulka BS, et al,. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993; 2: 467-72
14. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P,. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels. Cancer Causes Control 2000; 11: 847-52
15. Tuohimaa P, Tenkanen L, Ahonen M, et al,. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004; 108: 104-8 (Pubitemid 37444451)
16. Li H, Stampfer MJ, Hollis JB, et al,. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007; 4: 562-71 (Pubitemid 46495324)
17. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW,. Prostate cancer and prediagnostic levels of serum vitamin D metabolites. Cancer Causes Control 1995; 6: 235-9
18. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ,. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996; 5: 121-6
19. Nomura AM, Stemmermann GN, Lee J, et al,. Serum vitamin D metabolite levels and the subsequent development of prostate cancer. Cancer Causes Control 1998; 9: 25-32
20. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E,. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004; 15: 255-65 (Pubitemid 38988034)
21. Jacobs ET, Giuliano AR, Martínez ME, Hollis BW, Reid ME, Marshall JR,. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 2004; 89-90: 533-7 (Pubitemid 38844343)
22. Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA,. Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 2007; 16: 2784-6 (Pubitemid 351196338)
23. Ahn J, Peters U, Albanes D, et al,. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008; 100: 796-804 (Pubitemid 351809669)
24. Travis RC, Crowe FL, Allen NE, et al,. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol 2009; 169: 1223-32
25. Barnett CM, Nielson CM, Shannon J, et al,. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control 2010; 21: 1297-303
26. Schwartz GG, Hanchette CL,. UV, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same. Cancer Causes Control 2006; 17: 1091-101 (Pubitemid 44290774)
27. Grant WB,. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer. 2002; 94: 1867-75 (Pubitemid 34241126)
28. St-Hilaire S, Mannel S, Commendador A, Mandal R, Derryberry D,. Correlations between meteorological parameters and prostate cancer. Int J Health Geogr 2010; 9: 19
29. Luscombe CJ, Fryer AA, French ME, et al,. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 2001; 358: 641-2 (Pubitemid 32786834)
30. Luscombe CJ, French ME, Liu S, et al,. Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes. Carcinogenesis 2001; 22: 1343-7 (Pubitemid 32898688)
31. Bodiwala D, Luscombe CJ, Liu S, et al,. Prostate cancer risk and exposure to ultraviolet radiation: further support for the protective effect of sunlight. Cancer Lett 2003; 192: 145-9 (Pubitemid 36369268)
32. Bodiwala D, Luscombe CJ, French ME, et al,. Associations between prostate cancer susceptibility and parameters of exposure to ultraviolet radiation. Cancer Lett 2003; 200: 141-8 (Pubitemid 38366094)
33. John EM, Dreon DM, Koo J, Schwartz GG,. Residential sunlight exposure is associated with a decreased risk of prostate cancer. J Steroid Biochem Mol Biol 2004; 89-90: 549-52 (Pubitemid 38844346)
34. Weymouth G, Le Marshall J,. An operational system to estimate global solar exposure over the Australian region from satellite observations. Aust Met Mag 1999; 48: 181-95
35. Cechet RP,. Validation of GMS-5 S-VISSR solar exposure estimates over the Australian continent. Geoscience and Remote Sensing Symposium, 2001. IGARSS '01. Sydney: IEEE 2001 International, Vol. 2. 2001: 606-9 (Pubitemid 34236862)
36. Centre for Epidemiology and Research. New South Wales School Students Health Behaviours Survey: 2008 Report. Sydney: NSW Department of Health, 2009
37. McKinley A, Janda M, Auster J, Kimlin M,. In vitro model of vitamin D synthesis by UV radiation in an Australian urban environment. Photochem Photobiol 2010: published online
38. Robinson WS,. Ecological correlations and the behavior of individuals. Am Sociol Rev 1950; 15: 351-7
39. Coory MD, Baade PD,. Urban-rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing. Med J Aust 2005; 182: 112-5 (Pubitemid 40268252)
40. Smith DP, Armstrong BK,. Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales. Med J Aust 1998; 169: 17-20 (Pubitemid 28330453)
41. Sim HG, Cheng CW,. Changing demography of prostate cancer in Asia. Eur J Cancer 2005; 41: 834-45 (Pubitemid 40467547)
42. Moore SP, O'Rourke PK, Mallitt KA, et al,. Cancer incidence and mortality in indigenous Australians in Queensland, 1997-2006. Med J Aust 2010; 193: 590-3
43. Stanford JL, Ostrander EA,. Familial prostate cancer. Epidemiol Rev 2001; 23: 19-23. (Pubitemid 32906609)